Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial

IMPORTANCE: There are substantial unmet therapeutic needs in patients with platinum-resistant recurrent ovarian cancer (PROC), and novel therapeutic strategies should be explored. OBJECTIVE: To evaluate the efficacy and safety of treatment with apatinib (a vascular endothelial growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tiantian, Tang, Jie, Yang, Hongying, Yin, Rutie, Zhang, Jingru, Zhou, Qi, Liu, Ziling, Cao, Lanqin, Li, Li, Huang, Yi, Jiang, Kui, Wang, Wei, She, Fenglin, Guan, Ni, Hou, Zhiguo, Li, Ning, Wu, Lingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247861/
https://www.ncbi.nlm.nih.gov/pubmed/35771546
http://dx.doi.org/10.1001/jamaoncol.2022.2253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247861/
https://www.ncbi.nlm.nih.gov/pubmed/35771546
http://dx.doi.org/10.1001/jamaoncol.2022.2253

Ejemplares similares